2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
Wu J, Strober B, Hansen P, Ahlehoff O, Egeberg A, Qureshi A, Robertson D, Valdez H, Tan H, Wolk R. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal Of The American Academy Of Dermatology 2016, 75: 897-905. PMID: 27498960, DOI: 10.1016/j.jaad.2016.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCardiovascular DiseasesCholesterolClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicComorbidityC-Reactive ProteinDyslipidemiasFemaleGlycated HemoglobinHumansMaleMetabolic SyndromeMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesRisk FactorsTreatment OutcomeTriglyceridesConceptsMajor adverse CV eventsCV risk factorsTotal/HDL cholesterol ratioEffects of tofacitinibHDL cholesterol ratioIncidence rateLow-density lipoproteinRisk factorsPlaque psoriasisCholesterol ratioLong-term extension dataC-reactive protein levelsHigh-density lipoprotein cholesterolAdverse CV eventsCardiovascular risk factorsSystemic inflammatory conditionsDose-dependent increaseCV eventsTofacitinib dosesCardiovascular outcomesLipoprotein cholesterolBlood pressureTofacitinib treatmentTotal cholesterolHemoglobin levels
2014
Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities
Shlyankevich J, Mehta N, Krueger J, Strober B, Gudjonsson J, Qureshi A, Tebbey P, Kimball A. Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. The American Journal Of Medicine 2014, 127: 1148-1153. PMID: 25149424, PMCID: PMC4259841, DOI: 10.1016/j.amjmed.2014.08.008.Peer-Reviewed Original Research
2009
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
Kalb R, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. Journal Of The American Academy Of Dermatology 2009, 60: 824-837. PMID: 19389524, DOI: 10.1016/j.jaad.2008.11.906.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisUse of methotrexateLiver biopsyNational Psoriasis Foundation Medical BoardAppropriate patient selectionNational Psoriasis FoundationEvidence-based studiesMedical boardsMethotrexate therapyPatient selectionRheumatoid arthritisTreatment optionsHepatic fibrosisRisk factorsConsensus conferencePsoriasisSide effectsEffective drugsLast guidelinesMethotrexateValuable optionTreatmentBiopsyTask ForceReport